Pediatric Amikacin Therapy: Unveiling Adverse Drug Reactions through a Pharmacovigilance Study at AIIMS, Bathinda Amikacin Induced Adverse Drug Reaction in Pediatric Patients
Iranian Journal of Pharmaceutical Sciences,
مجلد 20 عدد 1 (2024),
8 اردیبهشت 2024
,
الصفحة 1-11
https://doi.org/10.22037/ijps.v20i1.43873
الملخص
Amikacin is commonly prescribed to pediatric patients as a bactericidal antibiotic. However, limited scientific data is available to determine safe and toxic levels in this population. This study aims to raise awareness among healthcare professionals about the adverse drug reactions associated with Amikacin therapy in pediatric patients and improve patient care and safety. The study involved a pharmacovigilance awareness program for healthcare professionals at the Pharmacovigilance unit of All India Institute of Medical Sciences (AIIMS), Bathinda. Patients reported adverse drug reactions (ADRs) through various means, such as phone or WhatsApp. The ADR reports were evaluated for demographic and ADR attributes such as date of onset, management description, causality, and overall event outcome. The causality of each ADR was determined using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) scale and Naranjo algorithm, and the severity was determined using the Modified Hartwig and Siegel Scale. Out of 60 pediatric patients given Amikacin, 5 reported adverse drug reactions. Most patients reporting ADRs were female, with a median age of 9 years and a median duration of one day. The adverse drug reactions were primarily skin-related and non-serious. The study highlights the need for a national-level control of preventable adverse drug reactions and a pediatric pharmacovigilance system in healthcare facilities. The data collected from this study will be used by the National Coordination Centre, Pharmacovigilance Programme of India, to create a drug alert and improve patient care and safety at the national level.
- Adverse drug reaction
- Amikacin
- Pediatric patients
- Antibiotics
- Intramuscular: Awareness
كيفية الاقتباس
المراجع
Siddiqi A, Khan DA, Khan FA, Razzaq A. Therapeutic drug monitoring of amikacin in preterm and term infants. Singapore Med J. 2009 May;50(5):486–9.
Priyadharsini R, Surendiran A, Adithan C, Sreenivasan S, Sahoo FK. A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacother. 2011 Oct;2(4):277–80.
D’Errico S, Zanon M, Radaelli D, Padovano M, Santurro A, Scopetti M, et al. Medication Errors in Pediatrics: Proposals to Improve the Quality and Safety of Care Through Clinical Risk Management. Front Med. 2021;8:814100.
Galande AD, Khurana NA, Mutalik S. Pediatric dosage forms-challenges and recent developments: A critical review. J Appl Pharm Sci. 2020 July 1;10(7):155–66.
Caceres Guido P, Perez M, Halac A, Ferrari M, Ibarra M, Licciardone N, et al. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis. Pediatr Pulmonol. 2019;54(11):1801–10.
Pacifici GM, Marchini G. Clinical Pharmacology of amikacin in infants and children. Clin Med Investig [Internet]. 2019 [cited 2024 January 6];5(1). Available from: https://www.oatext.com/clinical-pharmacology-of-amikacin-in-infants-and-children.php
Illamola SM, Sherwin CM, van Hasselt JGC. Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2018 Oct;57(10):1217–28.
Jenkins A, Thomson AH, Brown NM, Semple Y, Sluman C, MacGowan A, et al. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. J Antimicrob Chemother. 2016 Oct;71(10):2754–9.
Pacifici and Marchini - 2019 - Clinical Pharmacology of amikacin in infants and c.pdf [Internet]. https://www.oatext.com/pdf/CMI-5-199.pdf
Kato H, Hamada Y. Amikacin Therapy in Japanese Pediatric Patients: Narrative Review. Int J Environ Res Public Health. 2022 Feb 10;19(4):1972.
Oliveira JS de, Rodrigues LB, Aurélio FS, Silva VB da. Risk factors and prevalence of newborn hearing loss in a private health care system of Porto Velho, Northern Brazil. Rev Paul Pediatr Orgao Of Soc Pediatr Sao Paulo. 2013 Sep;31(3):299–305.
Dilley M, Geng B. Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole. Clin Rev Allergy Immunol. 2022 Jun;62(3):463–75.
Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract. 2014 Dec;27(6):573–7.
Downes KJ, Hayes M, Fitzgerald JC, Pais GM, Liu J, Zane NR, et al. Mechanisms of antimicrobial-induced nephrotoxicity in children. J Antimicrob Chemother. 2020 Jan;75(1):1–13.
Bock BV, Edelstein PH, Meyer RD. Prospective comparative study of efficacy and toxicity of netilmicin and amikacin. Antimicrob Agents Chemother. 1980 Feb;17(2):217–25.
Kovačević T, Avram S, Milaković D, Špirić N, Kovačević P. Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients. J Basic Clin Pharm. 2016 Jun;7(3):65–9.
Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119–26.
Gambôa I, Sousa PD, Duarte D, Oliveira N. Amikacin Ototoxicity: Case Report and Literature Review. Otolaryngol Online J. 2018 https://www.semanticscholar.org/paper/Amikacin-Ototoxicity%3A-Case-Report-and-Literature-Gamb%C3%B4a-Sousa/d3cea16c7c714d03690bf3fd1265955c93e2134a
Arulappen AL, Danial M, Sulaiman SAS. Evaluation of Reported Adverse Drug Reactions in Antibiotic Usage: A Retrospective Study From a Tertiary Care Hospital, Malaysia. Front Pharmacol. 2018;9:809.
SK A, Y H. Drug utilization study on pediatric pneumonia patients in a tertiary care teaching hospital. Int J Health Care Biol Sci. 2021 October 28;70–4.
Romano S, Fdez de Gatta MM, Calvo MV, Caballero D, Dominguez-Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother. 1999 Aug;44(2):235–42.
Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. Indian J Med Paediatr Oncol Off J Indian Soc Med Paediatr Oncol. 2016;37(1):42–6.
Bailey C, Peddie D, Wickham ME, Badke K, Small SS, Doyle-Waters MM, et al. Adverse drug event reporting systems: a systematic review. Br J Clin Pharmacol. 2016;82(1):17–29.
Hs R, D C, Rk S, R M. Adverse drug reactions: trends in a tertiary care hospital. Curr Drug Saf [Internet]. 2012 November 1 [cited 2023 October 25];7(5). https://pubmed.ncbi.nlm.nih.gov/23150923/
Z K, Y K, O K. Evaluation of Adverse Drug Reactions in Paediatric Patients: A Retrospective Study in Turkish Hospital. Front Pharmacol [Internet]. 2021 November 12 [cited 2023 October 25];12. Available from: https://pubmed.ncbi.nlm.nih.gov/34867419/
Keche Y, Gaikwad N, Dhaneria S. Preventability, predictability, severity and causality assessment of adverse drug reactions reported from a teaching hospital in chhattisgarh: A retrospective analysis. J Fam Med Prim Care. 2021 Jul;10(7):2541–5.
Geer MI, Koul PA, Tanki SA, Shah MY. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. J Pharmacol Toxicol Methods. 2016 Sep 1;81:323–34.
Lihite R, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, et al. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alex J Med. 2016 Jun 1;53.
Adverse drug reactions (ADRS) reporting: awareness and reasons of under-reporting among health care professionals, a challenge for pharmacists. https://springerplus.springeropen.com/articles/10.1186/s40064-016-3337-4
Dittrich ATM, Smeets NJL, de Jong EFM, Kämink JL, Kroeze Y, Draaisma JMT, et al. Quality of Active versus Spontaneous Reporting of Adverse Drug Reactions in Pediatric Patients: Relevance for Pharmacovigilance and Knowledge in Pediatric Medical Care. Pharmaceuticals. 2022 Sep;15(9):1148.
Joshi D, Gupta S, Singh TG, Parashar A, Singh SK. A Qualitative Evaluation of ADR Reporting in India: Non-Regulatory Confronts and Their Possible Solutions. ECS Trans. 2022 Apr 24;107(1):6763.
Alsaleh FM, Alzaid SW, Abahussain EA, Bayoud T, Lemay J. Knowledge, attitude and practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working in secondary and tertiary governmental hospitals in Kuwait. Saudi Pharm J. 2017 September 1;25(6):830–7.
Lack of Awareness of Pharmacovigilance among Young Healthcare Professionals in India: An Issue Requiring Urgent Intervention - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082015.
Jose J, Rao PGM. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res. 2006 September 1;54(3):226–33.
- الملخص المشاهدات: 201 الأوقات
- IJPS_Volume20_Issue1_Pages1-11 (English) التنزيلات: 150 الأوقات